Johns Hopkins HIV Guide
Adefovir
INDICATIONS
FDA
FDA
- Chronic hepatitis B in patients 12 years of age and older
NOTE: FDA-labeled indication is unchanged. The AASLD-IDSA 2026 practice guideline expanded HBV treatment eligibility broadly (e.g., immune-active disease, immune-tolerant patients over age 40), but adefovir is not among the recommended agents for any of these criteria.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 5, 2026
Citation
Soto, Caitlin, and Janessa M Smith. "Adefovir." Johns Hopkins HIV Guide Johns Hopkins HIV Guide, The Johns Hopkins University, 2026. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545230/all/Adefovir.
Soto C, Smith JM. Adefovir. Johns Hopkins HIV Guide Johns Hopkins HIV Guide. The Johns Hopkins University; 2026. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545230/all/Adefovir. Accessed October 12, 2026.
Soto, C., & Smith, J. M. (2026). Adefovir. In Johns Hopkins HIV Guide Johns Hopkins HIV Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545230/all/Adefovir
Soto C, Smith JM. Adefovir [Internet]. In: Johns Hopkins HIV Guide Johns Hopkins HIV Guide. The Johns Hopkins University; 2026. [cited 2026 October 12]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545230/all/Adefovir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Adefovir
ID - 545230
A1 - Soto,Caitlin,PharmD, BCIDP
AU - Smith,Janessa,Pharm.D., BCPS
Y1 - 2026/10/05/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545230/all/Adefovir
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
